Paasa Logo

SIX Swiss Exchange · Healthcare

Invest in MindMaze Therapeutics stock from India

Indian and foreign residents can buy MindMaze Therapeutics (MMTX) shares directly through Paasa.

By Paasa · Updated

MindMaze Therapeutics at a glance

Price
CHF 0.15+CHF 0.00 (0.68%)
Market cap
CHF 23.45M
Day range
CHF 0.15 – CHF 0.15
P/E
—
Dividend yield
None
Volume
30.64K
1 month
-23.06%
6 months
-58.67%
YTD
-92.17%
1 year
—
5 years
—

Live chart and statistics

Peer comparison

CompanyTickerPriceMarket cap
YpsomedYPSN.SWCHF 365.00CHF 4.80B
Oxford Nanopore TechnologiesONTTF$2.61$2.55B
Kuros BiosciencesKURN.SWCHF 18.16CHF 716.22M
Santhera PharmaceuticalsSANN.SWCHF 15.18CHF 225.14M
Newron PharmaceuticalsNWRN.SWCHF 8.36CHF 173.94M
WISeKey InternationalWIHN.SWCHF 10.60CHF 81.45M
EvoNextEVE.SWCHF 2.21CHF 15.94M
Addex TherapeuticsADXN$2.95$3.63M

Peers as grouped by the data provider. This is not an investment recommendation.

How to invest in MindMaze Therapeutics from India

  1. Step 1

    Open your Paasa account

    KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Step 2

    Add funds from your Indian bank account

    Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.

  3. Step 3

    Search MMTX and buy

    Find MindMaze Therapeutics by name or by its ticker, MMTX, and place your order.

Why invest in MindMaze Therapeutics from India

What MindMaze Therapeutics does

MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics’ neurotherapeutics ecosystem; and the patient app,… MindMaze Therapeutics operates in the Biotechnology industry within the Healthcare sector.

Paasa handles the paperwork

Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.

Frequently asked questions

Can I buy MindMaze Therapeutics stock from India?

Yes. Indian residents and NRIs can buy MindMaze Therapeutics (MMTX) shares directly through Paasa. MindMaze Therapeutics is listed on the SIX Swiss Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.

What tax do I pay in India when I sell MindMaze Therapeutics shares?

In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.

Share this guide
Get started

Own global companies from India, safeguard against rupee depreciation

Book a short call with our team to understand how Paasa can work for you